However, trial data also showed increased acute cellular rejection within the first-year post-transplant [8], with other reports linking CTLA-4 inhibitors with new onset psoriasis [9] and chilblain lupus [10]. This evidence concerns the gene CTLA4 and systemic lupus erythematosus.